FDA Drafts New Rules for Safer Blood Hepatitis B Checks
Published Date: 7/16/2025
Notice
Summary
The FDA just shared new draft advice for blood centers on how to test donations for hepatitis B to keep blood safer. This update affects anyone who collects whole blood or plasma and aims to replace old testing rules from 2012 and 1987. Blood centers should get ready for these changes, which could improve safety without adding big costs or delays.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
New FDA Hepatitis B Testing Guidance
If you collect whole blood or blood components (including Source Plasma), the FDA has issued a draft guidance with recommendations for testing donations for hepatitis B surface antigen (HBsAg). The draft guidance, when finalized, is intended to supersede the October 2012 guidance and the December 1987 memorandum on HBsAg testing to reduce the risk of transfusion-transmitted hepatitis B virus (HBV).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12239 — Agency Information Collection Activities; Proposed Collection; Comment Request; Extralabel Drug Use in Animals
The FDA wants your thoughts on how they collect info about using drugs in animals in ways not originally approved (called extralabel use). This affects vets, farmers, and animal drug makers who report this info. You’ve got until August 17, 2026, to share your comments—no cost changes, just making sure the paperwork is clear and easy.
2026-12236 — SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams
SpecGx LLC has asked the FDA to withdraw its approval for three strengths (27 mg, 36 mg, and 54 mg) of its methylphenidate extended-release tablets, effective June 18, 2026. This means these specific versions of the medicine will no longer be allowed on the market. Patients and pharmacies using these doses should look for alternatives, but no extra costs or penalties are mentioned.
2026-12235 — Advisory Committee; Science Board to the Food and Drug Administration; Renewal
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12238 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements
The FDA is asking for public feedback by July 20, 2026, on their rules that keep dietary supplements safe and made right. These rules affect companies that make, package, label, or store supplements, helping ensure products are high quality without adding extra costs. This review keeps the safety standards up-to-date and clear for everyone involved.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
Previous / Next Documents
Previous: 2025-13270 — Takes of Marine Mammals Incidental to Specified Activities; Taking Marine Mammals Incidental to the Washington Department of Transportation Mukilteo Wingwalls Repair Project in Puget Sound, Washington
The Washington Department of Transportation wants to fix the Mukilteo Wingwalls in Puget Sound, which might accidentally bother some marine mammals. NMFS is thinking about giving permission for this, asking for public comments, and might renew the permit for one more year if everything goes well. This project affects local sea animals and could happen soon, so your voice matters!
Next: 2025-13273 — Proposed Collection; Comment Request
The Pentagon Force Protection Agency wants your thoughts on a new info collection plan to make sure it’s useful and not too much work. They’re checking if the questions they ask are clear, helpful, and easy to answer, possibly using tech to make it simpler. If you’re involved or interested, now’s the time to speak up before they finalize things!